The Food and Drug Administration has expanded the approval of Igalmi, a prescription film used for sudden agitation, to allow some adults to use it at home. The drug, also known as dexmedetomidine, is approved for episodes associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. The manufacturer announced the decision Monday. It has yet to give a date for the at-home launch.
The FDA approval record dates the decision to Nov. 13. Previously, a health professional had to supervise use in a care setting. The revised prescribing information describes when patients can take the drug without that supervision. The film treats an episode of agitation. Care for the underlying psychiatric condition continues separately, and the label says the safety and effectiveness of daily, long-term Igalmi use have yet to be studied.
What patients should discuss with their prescriber

The revised label advises against at-home use for adults 65 or older and people with liver impairment. It calls for checking heart rate, blood pressure and the risk of fainting or falls before treatment. The drug can cause drowsiness, low blood pressure and a slow heart rate. The label also warns about use in people with certain heart rhythm risks and about interactions with medicines that cause sedation, including opioids.
The FDA label advises people to wait at least eight hours after taking Igalmi before driving or operating machinery. A prescriber can review which medicines a patient already takes and discuss how the patient and household should respond if an episode continues. The instructions for use under medical supervision differ from the instructions for use at home.
What researchers studied at home
The 12-week randomized study focused primarily on safety and tolerability. In the active-drug group, 102 participants used Igalmi for 1,160 episodes of agitation. Those were episodes across the same group of people, many of whom used the drug more than once. Common effects reported with at-home use included drowsiness, dry mouth, dizziness, and numbness or tingling in the mouth.
Teva Pharmaceuticals, which acquired Igalmi in October, said it would announce its plans for the expanded use later. Its Nov. 16 announcement gave no launch date or price for at-home use.







